AUS
NZ
UK
CA
USA
IND
Highlights
- Indivior (LON:INDV) confirms withdrawal from the London Stock Exchange following its primary listing shift to the US
- Company cites higher trading volumes and cost efficiency on Nasdaq as reasons for the decision
- The London Stock Exchange continues to face company departures, adding pressure to retain and attract listings
FTSE 100 Drugmaker Indivior Exits London Listing Amid Broader Market Shifts
Pharmaceutical company Indivior (LON:INDV), active in addiction treatment therapies, operates within the healthcare and pharmaceutical sector. The company's withdrawal from the London Stock Exchange marks another significant shift within UK capital markets, which includes other constituents of the FTSE 100 index: FTSE 100. Recent trends reflect a wider pattern of UK-listed businesses adjusting their global market presence in favour of overseas exchanges.
Withdrawal from the London Market
Indivior has confirmed its plan to cancel its remaining London listing after having shifted its primary stock listing to the US-based Nasdaq exchange in the previous year. The decision follows a review by the company that focused on comparative trading volumes, shareholder distribution, and the administrative burdens associated with dual listings.
The company produces opioid addiction treatments, primarily Sublocade and Suboxone. Its decision to delist from London was driven by its strong commercial footprint in the US, where the majority of its revenue is generated. The US market remains central to Indivior’s operations, supported by the scale of the ongoing opioid crisis and the clinical demand for long-term addiction therapies.
Commercial Focus on the United States
Indivior's portfolio is closely aligned with the US healthcare market, where it generates the bulk of its earnings. Sublocade is administered monthly via injection and is used as part of a comprehensive treatment plan for adults recovering from opioid dependence. Suboxone, another key product, is administered orally through dissolvable films or tablets and supports similar clinical goals. The company has announced plans to discontinue Perseris, a schizophrenia treatment administered monthly, following reduced commercial viability.
While Sublocade revenue is expected to remain consistent with prior periods, Suboxone is facing sales pressure from increased availability of generic alternatives. The company acknowledged a marked decline in Suboxone sales volume, while also highlighting that newer products will face market saturation and pricing challenges.
Ongoing Realignment of Market Listings
The departure of Indivior adds to the list of companies opting to move away from UK capital markets. This trend includes the likes of Tui (LON:TUI), the travel company which consolidated its listing in Frankfurt. The London Stock Exchange has experienced a sharp rise in delistings, with several firms moving primary listings abroad or exiting public markets altogether. Figures from last year indicate the highest number of delistings since the financial crisis.
The London market has, however, received some reinforcement from new arrivals. The most recent example includes Valterra, a spin-off from Anglo American (LON:AAL), which now holds a dual listing in South Africa and London. The listing of Valterra may help balance the effects of high-profile exits such as Indivior, though structural challenges remain.
Historical Ties to the UK Market
Indivior originated as a spin-off from Reckitt Benckiser (LON:RKT) in 2014 and has since maintained a presence on the London Stock Exchange. Despite its UK roots, strategic realignment has moved the business into the North American financial and operational landscape. The company's head office is based in Virginia, reinforcing its alignment with US-based shareholder bases and capital flows.
Following executive changes earlier this year, with Joseph Ciaffoni taking over as chief executive, Indivior has indicated that revenue challenges remain a focus. The change in leadership came shortly after the company flagged an expected drop in top-line growth, due largely to pricing pressure and competitive market dynamics in its therapeutic segment.
Implications for London’s Capital Market Outlook
Indivior’s exit reflects ongoing challenges faced by the London Stock Exchange. The decision follows increasing concerns about trading liquidity, valuation disparities, and the broader competitiveness of UK capital markets compared to global peers. While some companies have sought alternative capital strategies through dual listings, others, such as Indivior, have opted for a complete shift in market presence.
The current pattern of exits has prompted broader discussion regarding the attractiveness and long-term viability of London as a financial hub for public companies. The need for regulatory updates and strategic repositioning of the UK’s financial markets continues to grow amid global capital reallocation trends.
